Palumbo Wealth Management LLC Sells 14,145 Shares of Seer, Inc. (NASDAQ:SEER)

Palumbo Wealth Management LLC decreased its holdings in shares of Seer, Inc. (NASDAQ:SEER) by 11.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 108,147 shares of the company’s stock after selling 14,145 shares during the quarter. Palumbo Wealth Management LLC’s holdings in Seer were worth $250,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of SEER. AQR Capital Management LLC bought a new position in Seer in the 2nd quarter valued at $30,000. Quadrature Capital Ltd grew its holdings in shares of Seer by 301.7% in the third quarter. Quadrature Capital Ltd now owns 57,088 shares of the company’s stock worth $112,000 after purchasing an additional 42,875 shares during the last quarter. XTX Topco Ltd purchased a new position in Seer in the 3rd quarter worth about $123,000. Barclays PLC lifted its holdings in Seer by 34.1% during the 3rd quarter. Barclays PLC now owns 64,426 shares of the company’s stock valued at $127,000 after buying an additional 16,382 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its position in Seer by 194.9% in the 3rd quarter. GSA Capital Partners LLP now owns 127,868 shares of the company’s stock valued at $252,000 after buying an additional 84,515 shares during the period. 75.20% of the stock is currently owned by hedge funds and other institutional investors.

Seer Price Performance

Shares of NASDAQ:SEER opened at $2.31 on Friday. The firm’s 50 day simple moving average is $2.34 and its 200-day simple moving average is $2.08. Seer, Inc. has a one year low of $1.53 and a one year high of $2.63.

Seer Profile

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.